August 2015 Volume 11, Issue 8
Volume 11, Issue 8 | August 2015
August 2015
In this Issue
Special Reports
Stem Cell Special Report: Germlines and gene-editing
After engineering SuperRat, is Superman far behind?Q&A
Q&A: Mush, you huskies!
DDNews talks to Sujay Jadhav of goBalto about the origin and direction of his companyEditor's Focus
Dog days of summer. Dog years of oncology?
According to economists at MIT, companies are underinvesting in long-term research on new cancer-fighting drugs; we should probably be concerned about thatCommentary
Of minimum wage and cancer drugs
They may not seem to be 'two great tastes that go great together' but columnist Peter Kissinger has some lessons and thoughts that arise from considering boosts to minimum wages and the costs of cancer therapeuticsGuest Commentary: An industrywide call for greater antibody information
Many in recent years have highlighted unreliability and irreproducibility of much science research, adding up to an estimated $28 billion wasted each year in irreproducible preclinical research in the United States alone and, arguably, the greatest need for change lies in the field of commercial antibodiesBusiness & Government Policy
Kythera going for $2.1 billion
Allergan looks to bolster existing facial aesthetics business with acquisitionPfizer launches precision medicine center in Chile
Thermo Fisher joining the effort as a corporate sponsor in initial lung cancer projectThe M&A roundup
Catching up with the latest big news and rumors of mergers and acquisitionsCrowdsourced diligence insights for investors
First-of-its-kind product from Propel(x) brings democratized approach that is useful for complex deep technology situationsOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsDiagnostics
Dialing up diagnostic efforts
QIAGEN kicks off a trio of diagnostic-focused partnerships in June and JulyOnward and upward for OPKO
Company clears first hurdle in its acquisition of Bio-Reference LaboratoriesDiagnosing cancer with bacteria
Engineered probiotics can reportedly detect tumors in the liverA gut feeling about biotherapy
Study shows predictive role of biotherapy monitoring in inflammatory bowel diseaseClinical Trials
CSL Behring advances therapeutics for hemophilia
Novel recombinant factor VIII single chain aimed at adolescents and adultsGuselkumab demonstrates efficacy in plaque psoriasis
Phase 2b results show that blockade of IL-23 resulted in significant skin clearance, with improvements through week 40Three years and a trio of targets
Epizyme, Celgene extend joint agreement on epigenetic therapies for cancer worth up to $610 millionA taste of one’s own medicine
Clinical data shows promise of durable results with CAR T cell therapyDiscovery
One step at a time against Alzheimer’s
Brain inflammation targeted in first drug discovery project from Dementia ConsortiumUbiquitous ubiquitins?
Almac Discovery and Genentech partner on ubiquitin-related target for potential cancer drugs‘We are the world’
Open Innovation Drug Discovery program expands to bring academia, scientists, researchers, biotechs together across the globeAn initial partnership for Invenra
Biopharmaceutical company strikes mAb deal with Oxford BioTherapeuticsResearch & Development
Casting off with CD206
BIND and Macrophage to explore possibility of Manocept-linked Accurins to target disease-associated macrophagesFrom the ground up with uPAR
Cancer Research UK invests in startup company’s novel cancer treatmentUK companies pair on libraries targeting the ubiquitin system
Agreement combines Ubiquigent biology expertise with Cyclofluidic chemistry platform to identify small-molecule librariesPredicting survival
UCSD researchers use biomarkers to gauge response to chemotherapyNuGEN sampling effort could accelerate cancer research
Scientists at NuGEN Technologies Inc. have simultaneously surveyed the RNA of more than 400 targeted genes in a single assay using next-generation sequencingPreclinical
Waste not, want not
GBSI survey says U.S. squanders $28 billion annually on flawed preclinical research, stalling discovery of new therapiesGoing right to the head
TNX-201 demonstrates significant analgesic effects in animal models of migraine and chronic painTwo for the price of one
Elsalys Biotech nets rights for anti-CD160 antibody with anti-angiogenic, immunomodulatory effectsEarly-stage immunotherapy
Genticel announces proof of concept for HPV therapeutic vaccine
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Driving gene therapy with nonviral vectors
Learn why nonviral vectors are on the rise in gene therapy development.
Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis
Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Advancing immuno-oncology research with cellular assays
Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
